INO-5150 SynCon Prostate cancer Initiate phase I clinical trial (2013)
Here is a list of what ino has in the pipeline coming out the next 6 months, dates are always subject to change, and the bio defense projects ino has are often kept quite about until completed,
Big pharma partnership(2013) expected according to CEO Joseph Kim
PENNVAX-B is designed treat and prevent HIV Final HIV-001 results expected in 1H 2013
PENNVAX-GP HIV type-1 clades A and C Initiate phase I clinical trial in 2013
Seasonal Flu (H1N1, elderly) Report interim phase I clinical data (2013)
DNA vaccine for leukemia Additional phase II data (2013)
Hepatitis C virus therapeutic INO-8000 Phase I/IIa clinical trial in HCV infected individuals (4Q 2013)
VGX-3100 SynCon® vaccine for cervical dysplasia/cancer Enrolling international phase II study; expect results 1Q 2014
SynCon® vaccines against malaria, foot-and-mouth disease (for animals), dengue fever, Chikungunya virus, and other tropical infectious diseases, some which pose potential risk for bioterrorism use.
(dates for us military funded projects aren't listed and often results come out randomly like they have recently)
Sentiment: Strong Buy
This is all **GREAT** news.... but I'm also waiting to hear of a pre-clinical study results on MRSA..... MRSA is also a huge health issue... Relatives and acquaintances have been exposed to MRSA,... and hospitals have had to bring out the "BIG GUNS" vaccines to try and combat MRSA... and there are reportedly strains of it that health organizations are unable to treat..... so I'm guessing INO may be researching the various strains of MRSA to develop a consensus SYNCON vaccine.... That would be just one more accolade to thrust INO into the limelight!!!
1.Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
Kyle you referred to the next six months, let's also take a look at the previous six:
1. May 14, 2013
Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man.
2. Apr 18, 2013
Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
Broadly targeted SynCon® H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain.
3. Jan 9, 2013
Inovio Pharmaceuticals to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year
Phase I/IIa Trial Follows Preclinical Study Demonstrating for First Time that a Multi-Antigen HCV Vaccine Can Generate Potent T-Cell Response in Liver.
4. Dec 10, 2012
Inovio's Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses.
Clinical Trial with Universal Vaccine Increases Response Rate of Subjects Generating Infection-Preventing Antibodies by 100% in Population Most at Risk for Flu Deaths.
5. Dec 6, 2012
Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial.
6. Nov 26, 2012
Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study.
7. Nov 12, 2012
Inovio Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential to Clear HBV in Liver.
Inovio Advances New Disease Therapy, Where 400 Million Patients Lack Effective Treatment.
All in only six months from a company of 120 million market cap, without debt and with enough cash for a year.
Sentiment: Strong Buy
Also any news for Ebola/Marburg viruses, smallpox or othe potential terrorism dangers, for which INOVIO is thrifty to make announcements often...
News and updates about its collaborations and received grants from state institutions or other institutions like PATH Malaria, come out from time to time, as well.
IMO, I believe in 2013 news about a collaboration with a big pharma will come out also. A month ago Dr. Kim stated that INOVIO is in late stage discussions with big pharmas, I believe will be a deal in the next months. But, let's keep it in mind as a possibility only.
I nominate you to be the "Keeper of the Clinical Trial List." Also known as the "KCTL go to person." This is a real helpful tool in Longs monitoring and searching for important information as Inovio goes forward. Thanks for the summary.
Sentiment: Strong Buy